鲁索替尼乳膏或是治疗白癜风的有效药物

Vitiligo is a common clinical depigmentation disease, which is mainly characterized by local skin or mucous membrane white spots caused by the loss of functional melanocytes. Its pathogenesis is complex, and multiple factors are involved in the loss of melanocytes, in which autoimmune response plays an important role. Or it is an effective drug for treating vitiligo, which can be well proven according to various studies.

The first time ruxolitinib topical preparation was used to treat vitiligo was a series of case studies: In 2017, Rothstein B et al. conducted this non-randomized, open-label clinical observation trial for 20 consecutive weeks. 11 patients with vitiligo were treated with topical 1.5% ruxolitinib cream (topical, bid). The study found that among the 9 patients who completed the trial, 76% of the facial symptoms were improved in 4 patients; among the 11 patients who were registered, an average of 23% of the patients' VASI was improved; among the 8 patients involving the extremities and trunk, only 3 patients had trunk symptoms and 1 acral symptoms improved, suggesting that ruxolitinib cream has different therapeutic effects on different parts of the skin, and the reason may be related to light exposure.

Subsequently, some studies conducted a phase II clinical trial of ruxolitinib cream. The results showed that after 24 weeks of topical ruxolitinib, the number of patients with VASI ≥ 50 in the experimental group was significantly greater than that in the control group; at the same time, the adverse reactions of topical ruxolitinib were mild, with only 10% to 15% of patients developing acne. In a 2019 phase III clinical randomized double-blind trial of 1.5% ruxolitinib cream in patients with vitiligo over 12 years old, after 28 weeks of topical treatment (bid), the patients all achieved good results.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.